Immuno-Oncology | Specialty

Frontline Atezolizumab Regimen Improves Survival for NSCLC

June 5th 2018

The combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel educed the risk of death by 22% compared with bevacizumab and chemotherapy in patients with advanced wild-type non-squamous non–small cell lung cancer.

Dr. Jotte on the IMpower131 Findings in Squamous NSCLC

June 4th 2018

Robert M. Jotte, MD, PhD, medical director and co-chair, USON Thoracic Committee, Rocky Mountain Cancer Centers, discusses the phase III findings of the IMpower131 trial, which looked at the addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel (Abraxane) in patients with advanced squamous non

Dr. Sznol Discusses Immunotherapy Combinations in RCC

June 1st 2018

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses immunotherapy combinations in renal cell carcinoma.

Studies Stopped for Daratumumab/Checkpoint Inhibitor Combos in NSCLC, Myeloma

May 29th 2018

Two separate early-phase clinical trials exploring daratumumab in combination with either a PD-1 inhibitor for multiple myeloma or a PD-L1 inhibitor for non–small cell lung cancer were terminated following a planned interim analysis.

Durvalumab Improves Survival in Stage III NSCLC

May 25th 2018

Durvalumab significantly improved overall survival versus placebo when used as a sequential treatment in patients with locally-advanced, unresectable non–small cell lung cancer who had not progressed following standard chemoradiotherapy, according to updated findings from the phase III PACIFIC trial.

Novel Immunotherapy Shows Early Efficacy in Uveal Melanoma

May 22nd 2018

IMCgp100, a novel immune-based treatment, demonstrated a 1-year survival rate of 73% for patients with heavily pretreated, which is nearly double the historical expectations for patients with the disease.

A Whirlwind of Change in Lung Cancer

May 22nd 2018

Novel combination regimens anchored by pembrolizumab (Keytruda), atezolizumab (Tecentriq), or nivolumab (Opdivo) are opening the door to new options and an opportunity to personalize therapy in non–small cell lung cancer.

FDA Warns Against Single-Agent Checkpoint Inhibition for PD-L1-Low Untreated Urothelial Carcinoma

May 19th 2018

The FDA has issued a drug safety notification warning against the use of frontline single-agent immune checkpoint inhibition for patients with PD-L1–low expressing platinum-eligible urothelial carcinoma.

Debating Value Versus Cost for Immunotherapy

May 16th 2018

In March, the President’s Cancer Panel issued a report acknowledging the financial toxicity associated with cancer care across the spectrum of treatments and suggesting potential remedies.

Biomarker Dilemma Persists With Immunotherapy in Bladder Cancer

May 15th 2018

The quest continues to identify a predictive biomarker of response to more precisely treat patients with checkpoint inhibitors that, while markedly beneficial to some patients, are not without their own costs and associated immune-related adverse effects.

Blueprint for Tackling Toxicities From Checkpoint Blockade Agents Is Introduced

May 14th 2018

The National Comprehensive Cancer Network has developed its first set of recommendations to help clinicians manage toxicities in the recognition of the variety of immune-related adverse events that patients receiving checkpoint blockade immunotherapy may experience.

Dr. Patel Discusses Impact of Immunotherapy on NSCLC

May 11th 2018

Sandip P. Patel, MD, medical oncologist, assistant professor of medicine, University of California, San Diego, discusses the impact of immunotherapy on the treatment of patients with non–small cell lung cancer.

Standard of Care Continues to Shift in RCC

May 11th 2018

Toni K. Choueiri, MD, discusses recent advancements and shares his insight on the future treatment landscape of patients with kidney cancer.

Dr. Balar on Impact of Durvalumab Plus Tremelimumab in Bladder Cancer

May 10th 2018

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the impact of the combination of durvalumab (Imfinzi) plus tremelimumab in metastatic bladder cancer.

Atezolizumab, Cobimetinib Combo Falls Short in Phase III mCRC Trial

May 10th 2018

Combination therapy with the PD-L1 inhibitor atezolizumab and the MEK inhibitor cobimetinib failed to improve overall survival versus regorafenib in previously treated patients with locally advanced or metastatic colorectal cancer, according to topline findings from the phase III IMblaze370 study.

Expert Underscores Importance of AE Management in GU Cancers

May 10th 2018

Xiao X. Wei, MD, MAS, discusses managing possible adverse events of different systemic therapies in kidney and bladder cancer.

Sonpavde Navigates the Evolving Bladder Cancer Landscape

May 9th 2018

Guru P. Sonpavde, MD, navigates through the treatment landscape of urothelial carcinoma.

FDA Grants Frontline Atezolizumab Priority Review for NSCLC

May 7th 2018

The FDA has granted a priority review to a supplemental biologics license application for atezolizumab for use in combination with bevacizumab, carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer.

FDA Approval Sought for Frontline Pembrolizumab Combo in Squamous NSCLC

May 3rd 2018

A supplemental biologics license application has been submitted to the FDA for the use of pembrolizumab in combination with standard chemotherapy as a treatment for patients with metastatic squamous non–small cell lung cancer.

Manipulating the T-Cell Receptor Yields Promising Immunotherapies

May 1st 2018

Components of the T-cell receptor complex, which links antigen recognition with T-cell activity and effector function, are being exploited for several types of cancer immunotherapy.